CGRP amplifies Substance P's inflammatory effects in the lungs by upregulating its receptor, revealing a neuropeptide partnership that drives airway hyperresponsiveness.
CGRP upregulates NK-1RCGRP increased the expression of Substance P's receptor at both the gene and protein level — meaning CGRP doesn't just cause its own inflammation, it makes the lungs more sensitive to Substance P's inflammatory effects.
What the researchers found
Two neuropeptides — Substance P (SP) and CGRP — work together to drive airway inflammation. After ozone exposure in guinea pigs, both SP and CGRP increased with the same timing and location pattern, with a strong correlation between their expression levels.
Critically, CGRP was shown to upregulate the Substance P receptor (NK-1R) at both mRNA and protein levels in lung tissue. This means CGRP doesn't just cause inflammation on its own — it amplifies Substance P's inflammatory effects by increasing the number of receptors SP can activate. This upregulation was mediated through PKA, Calmodulin-dependent Kinase, and Tyrosine Protein Kinase pathways.
Why it matters
Asthma affects hundreds of millions of people, and airway hyperresponsiveness is its hallmark feature. This study reveals that two neuropeptides released from the same nerve endings don't just act independently — they cooperate to amplify inflammation. CGRP essentially turns up the volume on Substance P's inflammatory signal by increasing its receptor numbers. Understanding this crosstalk could open new therapeutic strategies: blocking either peptide alone might not be enough if the other can compensate or amplify the response.
The numbers in context
SP peaked on day 2 post-ozone exposure · strong correlation between SP and CGRP expression · CGRP upregulated NK-1R at mRNA and protein levels · 3 signaling pathways involved (PKA, Calmodulin-dependent Kinase, Tyrosine Protein Kinase)
How the study worked
Guinea pigs were exposed to ozone inhalation to induce airway inflammation. SP, CGRP, and NK-1R receptor expression were measured at multiple time points using radioimmunoassay, immunohistochemistry, and in situ hybridization. Additionally, in vitro lung tissue cultures were used to directly test whether CGRP induces NK-1R expression and to identify the signaling pathways involved using specific kinase inhibitors.
Who was studied
Guinea pigs (in vivo ozone exposure model) and guinea pig lung tissue cultures (in vitro)
What this study cannot tell us
Animal study (guinea pigs) — results may not directly translate to human asthma. Ozone-induced inflammation is a model, not identical to allergic asthma. The study doesn't demonstrate therapeutic intervention (e.g., blocking CGRP or SP to reduce symptoms). In vitro tissue culture results need confirmation in whole-organism models.
How to read the evidence
Moderate evidence: a well-designed preclinical study combining in vivo animal models with in vitro mechanistic experiments and pathway analysis. The findings are internally consistent but limited to guinea pig models without human validation.
When this study was published
Published in 2007, this study established an important mechanistic concept. Since then, CGRP-targeted therapies have been developed for migraine (anti-CGRP antibodies), but the airway inflammation connection described here remains an active research area.
The bigger picture
This study connects two major neuropeptide research areas — Substance P (neurogenic inflammation) and CGRP (now a major migraine drug target) — in the context of lung disease. The discovery that CGRP amplifies SP signaling has implications beyond asthma: this crosstalk mechanism could be relevant wherever both peptides are active, including chronic pain, migraine, and inflammatory bowel disease. It also suggests that therapies targeting just one neuropeptide might be less effective if the other compensates.
Questions still open
- Could blocking CGRP reduce airway inflammation by preventing SP receptor upregulation — potentially repurposing migraine drugs for asthma?
- Does this SP-CGRP cooperative mechanism also operate in human lungs and contribute to treatment-resistant asthma?
- Are there other neuropeptide pairs that show similar cooperative amplification in inflammatory disease?
Common questions
How do Substance P and CGRP work together to cause airway inflammation?
Could CGRP-blocking drugs that treat migraines also help with asthma?
Read the original research
Upregulation of substance P receptor expression by calcitonin gene-related peptide, a possible cooperative action of two neuropeptides involved in airway inflammation.
Pulmonary pharmacology & therapeutics, 20(5), 513-24
Citation
Wu, Hong; Guan, Chaxiang; Qin, Xiaoqun; Xiang, Yang; Qi, Mingming; Luo, Ziqiang; Zhang, Changqing. (2007). Upregulation of substance P receptor expression by calcitonin gene-related peptide, a possible cooperative action of two neuropeptides involved in airway inflammation.. Pulmonary pharmacology & therapeutics, 20(5), 513-24.